Physician

Anita Mehrotra, M.D.

According to 2025 Medicare claims, Anita Mehrotra, M.D. (NPI: 1407065386) practices nephrology in the Camden, NJ market, with the plurality of this provider's patient population coming from Camden, NJ. This provider's primary affiliated billing organization is VIRTUA MEDICAL GROUP, PA (NPI: 1649226515; TIN: 271348772) and primary practice location at 08103-3101.

Mehrotra's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 136 traditional Medicare patients, billed 713 HCPCS/CPT codes, and received $70,280 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 3,012 prescription claims across 195 beneficiaries totaling $852,548 in drug costs, led by Veltassa (Patiromer Calcium Sorbitex). DME data shows 2,500 claims. Open Payments data shows 17 records totaling $818. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $41,640 to $70,280. Similarly, Part D prescription costs have risen steadily, from $53,944 to $852,548. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	132	334	$41,640
2016	25	35	$2,287
2017	N/R	N/R	N/R
2018	144	724	$59,149
2019	148	683	$55,831
2020	145	827	$70,564
2021	163	836	$85,425
2022	154	943	$95,981
2023	159	922	$95,438
2024	136	713	$70,280

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	24	411	$53,944
2016	N/R	85	$11,575
2017	N/R	N/R	N/R
2018	87	717	$89,638
2019	121	1,626	$241,230
2020	134	2,048	$1,004,537
2021	163	2,170	$516,767
2022	181	2,371	$497,186
2023	191	2,227	$1,257,309
2024	195	3,012	$852,548

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	296	1,296	$121,338
2019	388	3,210	$311,731
2020	479	4,091	$344,548
2021	500	4,124	$283,240
2022	498	3,940	$226,205
2023	524	3,901	$209,113
2024	346	2,500	$146,720

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	44	54	$142
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	23	24	$107
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	89	330	$102
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	51	200	$97
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	36	72	$65

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Veltassa	Patiromer Calcium Sorbitex	32	1,360	$34,388
Procrit	Epoetin Alfa	16	364	$33,866
Eliquis	Apixaban	27	1,290	$25,471
Atovaquone	Atovaquone	72	1,650	$23,912
Valganciclovir Hcl	Valganciclovir Hcl	186	6,286	$23,135

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7503	Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg	N	24	206	$99,303
J7518	Mycophenolic acid, oral, 180 mg	N	70	450	$17,645
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	84	718	$10,661
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	85	504	$8,830
J7507	Tacrolimus, immediate release, oral, 1 mg	N	55	426	$7,963

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	17	$818	Alexion Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Anita Mehrotra, M.D.?

Tedicare shows public-source Medicare data for Anita Mehrotra, M.D. (NPI 1407065386), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Anita Mehrotra, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Anita Mehrotra, M.D.?

Anita Mehrotra, M.D. is linked to VIRTUA MEDICAL GROUP, PA (billing NPI 1649226515) in the available physician profile data.

Does Anita Mehrotra, M.D. have Open Payments data?

Anita Mehrotra, M.D. has 17 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.